A novel in silico approach to drug discovery via computational intelligence

Journal of Chemical Information and Modeling

Volumn 49, Issue 4, 2009, Pages 1105-1121

  Hecht, David ^a   Fogel, Gary B ^b  

^a Southwestern College   (United States)

^b NATURAL SELECTION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; PROTEINS;

ANTIMALARIAL DRUG; DIHYDROFOLATE REDUCTASE; EXPERIMENTAL VALIDATIONS; FRAGMENT ASSEMBLY; HIGH THROUGHPUT; INNOVATIVE TECHNOLOGY; PROTEIN TARGETS; SMALL MOLECULES;

INTELLIGENT COMPUTING;

ANTIMALARIAL AGENT; CYCLOGUANIL; DIHYDROFOLATE REDUCTASE; DRUG; FOLIC ACID ANTAGONIST; PROGUANIL; TRIAZINE DERIVATIVE;

ALGORITHM; ARTICLE; ARTIFICIAL INTELLIGENCE; ARTIFICIAL NEURAL NETWORK; CHEMISTRY; COMPUTER SIMULATION; CONFORMATION; DRUG DESIGN; DRUG SCREENING; METHODOLOGY; MOLECULAR LIBRARY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGRESSION ANALYSIS; REPRODUCIBILITY; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ALGORITHMS; ANTIMALARIALS; ARTIFICIAL INTELLIGENCE; CHLOROGUANIDE; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FOLIC ACID ANTAGONISTS; MOLECULAR CONFORMATION; NEURAL NETWORKS (COMPUTER); PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES; TETRAHYDROFOLATE DEHYDROGENASE; TRIAZINES;

EID: 66149089880     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci9000647     Document Type: Article

References (61)

1. Schnecke, V.; Boström, J. Computational chemistry-driven decision making in lead generation. Drug Discovery Today 2006, 11, 43-50.
2. Good, A. C.; Krystek, S. R.; Mason, J. S. High-throughput and virtual screening: core lead discovery technologies move towards integration. Drug Discovery Today 2000, 5, S61-S69.
3. Anderson, A. C.; Wright, D. L. The design and docking of virtual compound libraries to structures of drug targets. Curr. Comput -Aided Drug Des. 2005, 1, 103-127.
4. Mauser, H.; Guba, W. Recent developments in de novo design and scaffold hopping. Curr. Opin. Drug Discovery Dev. 2008, 11, 365-374.
5. Jhoti, H. Fragment-based drug discovery using rational design. Ernst Schering Found. Symp. Proc. 2007, 3, 169-85.
6. Honma, T. Recent advances in de novo design strategy for practical lead identification. Med. Res. Rev. 2003, 23, 606-632.
7. Pearlman, D. A.; Murcko, M. A. CONCERTS: dynamic connection of fragments as an approach to de novo ligand design. J. Med. Chem. 1996, 39, 1651-1663.
8. Böhm, H. J. The computer program LUDI: A new method for the de novo design of enzyme inhibitors. J. Comput.-Aided Mol. Des. 1992, 6, 61-78.
9. Böhm, H. J. On the use of Ludi to search the Fine Chemical Directory for ligands of proteins of known 3-dimensional structure. J. Comput. -Aided Mol. Des. 1994, 8, 623-632.
10. Lauri, G.; Bartlett, P. A. CAVEAT: a program to facilitate the design of organic molecules. J. Comput. -Aided Mol. Des. 1994, 1, 51-66.
11. Tschinke, V.; Cohen, N. C. The NEWLEAD program: a new method for the design of candidate structures from pharmacophoric hypotheses. J. Med. Chem. 1993, 36, 3863-70.
12. Miranker, A.; Karplus, M. An automated method for dynamic ligand design. Proteins 1995, 23, 472-490.
13. Roe, D. C.; Kuntz, I. D. BUILDER v.2: Improving the chemistry of a de novo design strategy. J. Comput. -Aided Mol. Des. 1995, 9, 269-282.
14. Stahl, M.; Todorov, N. P.; James, T.; Mauser, H.; Boehm, H. J.; Dean, P. M. A validation study on the practical use of automated de novo design. J. Comput. -Aided Mol. Des. 2002, 16, 459-78.
15. Firth-Clark, S.; Kirton, S. B.; Willems, H. M.; Williams, A. De novo ligand design to partially flexible active sites: application of the ReFlex algorithm to carboxypeptidase A, acetylcholinesterase, and the estrogen receptor. J. Chem. Inf. Model. 2008, 48, 296-305.
16. Westhead, D. R.; Clark, D. E.; Frenkel, D.; Li, J.; Murray, C. W.; Robson, B.; Waszkowycz, B. PRO-LIGAND: An approach to de novo molecular design. 3. A genetic algorithm for structure refinement. J. Comput.-Aided Mol. Des. 1995, 9, 139-148.
17. Pegg, S. C.; Haresco, J. J.; Kuntz, I. D. A genetic algorithm for structure-based de novo design. J. Comput. -Aided Mol. Des. 2001, 15, 911-933.
18. Leapfrog, 6.8 ed.; Tripos, Inc.: St. Louis, MO.
19. Nishibata, Y.; Itai, A. Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation. Tetrahedron 1991, 47, 8985-8990.
20. Caflisch, A.; Miranker, A.; Karplus, M. Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase. J. Med. Chem. 1993, 36, 2142-2167.
21. Bohacek, R. S.; McMartin, C. Multiple highly diverse structures complementary to enzyme binding sites: Results of extensive application of de novo design method incorporating combinatorial growth. J. Am. Chem. Soc. 1994, 116, 5560-5571.
22. Rotstein, S. H.; Murcko, M. A. Genstar-a method for de novo drug design. J. Comput.-Aided Mol. Des. 1993, 7, 23-43.
23. DeWitt, R.; Shaknovich, E. SmoG: de novo design method based on simple, fast, and accurate free energy estimates. 1. Methodology and supporting evidence. J. Am. Chem. Soc. 1996, 118, 11733-11744.
24. DeWitt, R.; Shaknovich, E. SmoG: de novo design method based on simple, fast, and accurate free energy estimates. 2. Case studies on molecular design. J. Am. Chem. Soc. 1996, 119, 4608-4617.
25. Rotstein, S. H.; Murcko, M. A. Groupbuild-a fragment-based method for de novo drug design. J. Med. Chem. 1993, 36, 1700-1710.
26. Gillet, V. J.; Newell, W.; Mata, P.; Myatt, G.; Sike, S.; Zsoldos, Z.; Johnson, A. P. SPROUT: recent developments in the de novo design of molecules. J. Chem. Inf. Comput. Sci. 1994, 34, 207-17.
27. Moon, J.; Howe, W. Computer design of bioactive molecules: a method for receptor-based de novo ligand design. Proteins 1991, 11, 314-328.
28. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discovery 2004, 3, 935-949.
29. Leach, A. R.; Shoichet, B. K.; Peishoff, C. E. Prediction of protein ligand interactions. Docking and scoring: successes and gaps. J. Med. Chem. 2006, 49, 5851-5855.
30. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-Based Lead Discovery. Nat. Rev. Drug Discovery 2005, 3, 660-672.
31. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A 'rule of three' for fragment-based lead discovery. Drug Discovery Today 2003, 8, 876-877.
32. Böhm, H. J.; Stahl, M. Combinatorial docking and combinatorial chemistry: design of potent non-peptide thrombin inhibitors. J. Comput.-Aided Mol. Des. 1999, 13, 51.
33. Kick, E. K.; Roe, D. C.; Skillman, A. G.; Liu, G.; Ewing, T. J.; Sun, Y.; Kuntz, I. D.; Ellman, J. A. Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. Chem. Bid. 1997, 4, 297.
34. Todorov, N. P.; Dean, P. M. Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design. J. Comput.-Aided Mol. Des. 1997, 11, 175-192.
35. Murray, C. W.; Clark, D. E.; Auton, T. R.; Firth, M. A.; Li, J.; Sykes, R. A.; Waszkowycz, B.; Westhead, D. R.; Young, S. C. PRO-SE-LECT: Combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology. J. Comput Aided Mol. Des. 1997, 11, 193-207.
36. Fogel, G. B. Computational intelligence approaches for pattern discovery in biological systems. Briefings Bioinf. 2008, 9, 307-316.
37. Budin, N.; Ahmed, S.; Majeux, N.; Caflisch, A. An Evolutionary Approach for Structure-based Design of Natural and Non-natural Peptidic Ligands. Comb. Chem. High Throughput Screening 2001, 4, 661-673.
38. Belda, I.; Madurga, S.; Llorà, X.; Martinell, M.; Tarragó, T.; Piqueras, M. G.; Nicolás, E.; Giralt, E. ENDPA: an evolutionary structure-based de novo peptide design algorithm. J. Comput.-Aided Mol. Des. 2005, 19, 585-601.
39. Belda, I.; Madurga, S.; Tarragó, T.; Llorà, X.; Giralt, E. Evolutionary computation and multimodal search: A good combination to tackle molecular diversity in the field of peptide design. Mol. Diversity 2007, 11, 7-21.
40. Hou, T.; Xu, X. A new molecular simulation software package - Peking University Drug Design System (PKUDDS) for structure-based drug design. J. Mol. Gravhics Modell. 2001, 19, 455-465.
41. Douguet, D.; Munier-Lehmann, H.; Labesse, G.; Pochet, S. LEA3D: A Computer-Aided Ligand Design for Structure-Based Drug Design. J. Med. Chem. 2005, 48, 2457-2468.
42. Bandyopadhyay, S.; Bagchi, A.; Maulik, U. Active Site Driven Ligand Design: An evolutionary Approach. J. Bioinf. Comput. Biol. 2005, 3, 1053-1070.
43. Liu, Q.; Masek, B.; Smith, K.; Smith, J. Tagged Fragment Method for Evolutionary Structure-Based De Novo Lead Generation and Optimiziation. J. Med. Chem. 2007, 50, 5392-5402.
44. Dey, F.; Calfisch, A. Fragment-Based de Novo Ligand Design by Multiobjective Evolutionary Optimization. J. Chem Inf. Model. 2008, 48, 679-690.
45. Schüller, A.; Suhartono, M.; Fechner, U.; Tanrikulu, Y.; Breitung, S.; Scheffer, U.; Göbel, M. W.; Schneider, G. The concept of template-based de novo design from drug-derived molecular fragments and its application to TAR RNA. J. Comput.-Aided Mol. Des. 2008, 22, 59-68.
46. Hecht, D.; Fogel, G. B. High-throughput ligand screening via preclustering and rvolved neural networks. IEEE/ACM Trans. Comput. Biol. Bioinf. 2007, 4, 476.
47. Hecht, D.; Cheung, M.; Fogel, G. B. QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives. Biosystems 2008, 92, 10-15.
48. Cheung, M.; Johnson, S.; Hecht, D.; Fogel, G. B. Quantitative structure-property relationships for drug solubility prediction using evolved neural networks. IEEE Congr. Evol. Comput., Hong Kong 2008, xx.
49. Duffy, E. M.; Jorgensen, W. L. Prediction of Properties from Simulations: Free Energies of Solvation in Hexadecane, Octanol, and Water. J. Am. Chem. Soc. 2000, 122, 2878-2888.
50. Yazdanian, M.; Glynn, S. L.; Wright, J. L.; Hawi, A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm. Res. 1998, 15, 1490-1494.
51. Irvine, J. D.; Takahashi, L.; Lockhart, K.; Cheong, J.; Tolan, J. W.; Selick, H. E.; Grove, J. R. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 1999, 88, 28-33.
52. Stenberg, P.; Norinder, U.; Luthman, K.; Artursson, P. Experimental and computational screening models for the prediction of intestinal drug absorption. J. Med. Chem. 2001, 44, 1927-1937.
53. Yuvaniyama, J.; Chitnumsub, P.; Kamchonwongpaison, S.; Vanichtanankul, J.; Sirawaraporn, W.; Taylor, P.; Walkinshaw, M.; Yuthavong, Y. Insights into antifolate resistance from malarial DHFR-TS structures. Nat. Struct. Biol. 2003, 10, 357-365.
54. Parenti, M. D.; Pacchioni, S.; Ferrari, A. M.; Rastelli, G. Three-Dimensional Quantitative Structure-Activity Relationship Analysis of a set of Plasmodium falciparum Dihydrofolate Reductase Inhibitors Using a Pharmacophore Generation Approach. J. Med. Chem. 2004, 47, 4258-4267.
55. Kamchonwongpaison, S.; Quarrell, R.; Charoensetakul, N.; Ponsinet, R.; Vilaivan, T.; Vanichtanankul, J.; Tarnchampoo, W.; Sirawaraporn, W.; Lowe, G.; Yuthavong, Y. Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities. J. Med. Chem. 2004, 47, 673-680.
56. Kamchonwongpaison, S.; Vanichtanankul, J.; Tarnchampoo, B.; Yuvaniyama, J.; Taweechai, S.; Yuthavong, Y. Stoichiometric selection of tightbinding inhibitors by wild-type and mutant forms of malarial (Plasmodium falciparum) dihydrofolate reductase. Anal. Chem. 2005, 77, 1222-1227.
57. Santos-Filho, O. A.; Hopfinger, A. J. A Search for Sources of Drug Resistance by the 4D-QSAR Analysis of a Set of Antimalarial Dihydrofolate Reductase Inhibitors. J. Comput.-Aided Mol. Des. 2001, 15, 1-12.
58. Sutherland, J. J.; Weaver, D. F. Three-Dimensional Quantitative Structure-Activity and Structure-Selectivity Relationships of Dihydrofolate Reductase Inhibitors. J. Comput.-Aided Mol. Des. 2004, 18, 309-331.
59. Halgren, T. A. The merck force field. J. Comput. Chem. 1996, 17, 490-512.
60. Fogel, G. B.; Cheung, M.; Pittman, E.; Hecht, D. In Silico Screening Against Wild-Type and Mutant Plasmodium falciparum Dihydrofolate Reductase. J. Mol. Graphics Modell. 2008, 26, 1145-1152.
61. Fogel, G. B.; Cheung, M.; Pittman, E.; Hecht, D. Modeling the Inhibition of Quadruple Mutant Plasmodium falciparum Dihydrofolate Reductase by Pyrimethamine Derivatives. J. Comput.-Aided Mol. Des. 2008, 22, 29-38.